<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=192888919167017&amp;ev=PageView&amp;noscript=1">
Thursday, March 28, 2024
March 28, 2024

Linkedin Pinterest

Shopping advised for Medicare drug plans

Switching may save people on Plan D a premium increase

By RICARDO ALONSO-ZALDIVAR, Associated Press
Published: November 22, 2015, 9:38pm

WASHINGTON — With time running out on open enrollment season, many seniors are facing sharply higher premiums for Medicare’s popular prescription drug program. The reason: rising drug costs have overtaken a long stretch of stable premiums.

Beneficiaries have until Dec. 7 to see if there’s a lower-cost plan that will cover their medications in 2016. Consumer advocates and experts say it will pay to shop around this sign-up season.

“Premiums are going up. Deductibles are going up,” said Tricia Neuman, a Medicare expert with the nonpartisan Kaiser Family Foundation. “There is some potential to save a lot of money by switching plans.”

Government spending on the program also has risen significantly, driven by pricey new drugs, notably for hepatitis C infection. The cost for the hepatitis drugs in the Medicare program is expected to be $9.2 billion this year, a near doubling from 2014. Because of the prescription program’s financial structure, taxpayers cover most of the cost for expensive medications. Three out of four adults infected with hepatitis C are baby boomers, the group now entering Medicare.

Also known as “Part D,” Medicare’s prescription plan serves about 40 million older and disabled people. Benefits are provided through a variety of insurance arrangements. Stand-alone drug plans that work with traditional Medicare are the most popular, accounting for more than half of beneficiaries — about 24 million people.

Sal Natale, a retired dentist who lives near Tampa, Fla., said prescription premiums for him and his wife are going up about 30 percent next year, and he doesn’t see a good alternative.

“I’m just going to grin and bear and hope it starts moderating,” Natale said. The couple is signed up in the Humana Enhanced plan, one of the top 10. Nationally, premiums for that plan are going up by about $13 a month, according to the Kaiser foundation.

Independent estimates by Kaiser and the consulting firm Avalere Health show the average premium for stand-alone drug plans will rise from $36.68 to $41.46 per month next year, or 13 percent, according to Kaiser. Even if many beneficiaries switch to lower-cost options, it’s likely to be the biggest increase since 2009.

Those analyses are seemingly at odds with the message coming from the Obama administration, which estimates that drug premiums will remain stable in 2016, averaging $32.50 a month.

But the administration and the independent analysts measure differently.

The administration adjusts its number for the estimated impact on people, assuming many will switch to lower-premium plans.

The outside analysts focus on what happens if people stick to their current plans.

Nationally, average premiums are going up by more than 15 percent in five of the top eight plans, according to the Kaiser study. Two plans will see single-digit increases. One plan — SilverScript Choice — will see a small reduction. The most popular plan — AARP MedicareRx Preferred — will go up from $50.19 to $60.79, a 21 percent increase.

mobile phone icon
Take the news everywhere you go.
Download The Columbian app:
Download The Columbian app for Android on Google PlayDownload The Columbian app for iOS on the Apple App Store

Besides all that, the maximum deductible for prescription coverage — how much beneficiaries must pay for drugs each year before their insurance kicks in — will rise by $40, to $360. That’s the biggest increase in the deductible since the inception of Part D in 2006.

Sean Cavanaugh, deputy administrator at the Centers for Medicare and Medicaid Services, said the administration has a good track record with its estimates. “We do think ours is more illustrative of what beneficiaries actually experience,” he said.

Cavanaugh did say the administration is concerned about the cost of new breakthrough drugs. The insurers who deliver Medicare’s prescription benefit have limited options for bargaining down the prices of those medications, because usually there’s no competing alternative.

“The challenge in the Part D program is around high-cost specialty drugs,” said Cavanaugh. “We certainly have to be concerned about anything that’s driving that much cost in our program.”

With polls showing that drug costs are the top health care issue for the public, presidential candidates are weighing in. Options they propose range from giving Medicare direct authority to negotiate drug prices, backed by Democrat Hillary Rodham Clinton, to speeding up approval of new drugs, advanced by Republican Jeb Bush.

Consumer advocates are skeptical that seniors’ shopping for better deals will be sufficient to blunt the cost increases.

Finding a new plan can be overwhelming, said Bonnie Burns, a longtime Medicare counselor with nonprofit California Health Advocates. “People can’t deal with the complexity of deductibles, coverage tiers, and prior approval,” she said.

Natale, the Florida retiree, says he’s not sure what the right answer is. He’s wary of government controls on private industry, but the relentless growth of costs worries him.

“I really don’t think I have much of an option for protecting me and my wife if I get some serious illness and I need big-time drugs,” he said.

Loading...